Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Executive Summary
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin
You may also be interested in...
Boehringer/Lilly's Linagliptin Approved: Can Renal Flexibility Unlock The DPP-4 Market?
Tradjenta's label supporting use in renally-impaired patients, with no need to adjust dose, could help differentiate the product's safety profile in a competitive space.
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.